Chemical Component Summary

NameL-deoxythymidine
Identifiers1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione
FormulaC10 H14 N2 O5
Molecular Weight242.23
TypeNON-POLYMER
Isomeric SMILESCC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O
InChIInChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1
InChIKeyIQFYYKKMVGJFEH-CSMHCCOUSA-N

Chemical Details

Formal Charge0
Atom Count31
Chiral Atom Count3
Bond Count32
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB01265 
NameTelbivudine
Groups
  • approved
  • investigational
DescriptionTelbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.
Synonyms
  • L-DT
  • β-L-2'-deoxythymidine
  • 1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil
  • Telbivudin
  • Beta-l-thymidine
Brand Names
  • Tyzeka
  • Sebivo
IndicationFor the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Categories
  • Anti-Infective Agents
  • Antiinfectives for Systemic Use
  • Antiviral Agents
  • Antivirals for Systemic Use
  • Carbohydrates
ATC-CodeJ05AF11
CAS number3424-98-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Protein PMPLSYPHFRKLLLLDDEAGPLEEELPRLADEDLNRRVAADLNLQLPNVSI...unknown
DNA-unknown
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem159269
ChEBICHEBI:63624
ChEMBLCHEMBL374731